drugset
drugset / Trial / NCT05972928

Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

NCT05972928 ↗

Phase 2/3 Unknown 80 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelTreatment

Summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility

Timeline

Start
2023-07-30
Primary completion
2023-10-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg —

Indications

polycystic ovary syndrome